2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by KIMURA, H. Articles by ARAKAWA, M. Search for Related Content PubMed PubMed Citation Articles by KIMURA, H. Articles by ARAKAWA, M.

A Cholesteryl Ester Transfer Protein Gene Mutation and Vascular Disease in Dialysis Patients

HIDEKI KIMURA^*, FUMITAKE GEJYO^*, TOMOKO YAMAGUCHI^*, SATORU SUZUKI^*, TOSHIO IMURA^*, RYOICHI MIYAZAKI and MASAAKI ARAKAWA

^* Department of Clinical and Laboratory Medicine, Faculty of Medicine, Fukui Medical University, Fukui, Japan
Fujita Memorial Hospital, Fukui, Japan
Department of Medicine (II), Niigata University School of Medicine, Niigata, Japan.

Correspondence to Dr. Hideki Kimura, Department of Clinical and Laboratory Medicine, Faculty of Medicine, Fukui Medical University, 23 Shimoaitsuki, Matsuoka, Yoshida Fukui 910-11 Japan. Phone: 0776-61-3111, extension 2412; Fax: 0776-61-8120; E-mail: hkimura{at}fmsrsa.fukui-med.ac.jp

Abstract. Among patients undergoing maintenance hemodialysis, a decreased high-density lipoprotein cholesterol (HDL-C) concentration is among the most common abnormalities of lipid metabolism and apparently is an independent risk factor for vascular disease. A common missense mutation of cholesteryl ester transfer protein gene, D442G (Asp 442 to Gly), increases HDL-C levels through the reduced activity of cholesteryl ester transfer from HDL to VLDL, but the mutation also may lead to reduced activity of reverse cholesterol transport. To investigate the effect of the D442G polymorphism on atherosclerotic complications in dialysis patients, the genotype and allele frequency of the polymorphism were determined in 414 unselected dialysis patients and 220 control subjects, and postprandial serum lipid levels were measured in the dialysis patients. A similar genotype distribution was found between hemodialysis patients and healthy control subjects, and in dialysis patients with and without vascular disease. Serum levels of total cholesterol and HDL-C did not differ between patients with and without the mutation and in patients with and without vascular disease. However, patients with sub-median HDL-C levels (<45 mg/dl) had an independent odds ratio of 1.8 for vascular disease (95% confidence interval, 1.04 to 3.2; P < 0.05). In this low-HDL-C subgroup, patients with the D442G mutation had a significantly higher prevalence of vascular disease than those with no mutation (54.5% versus 24.4%; P < 0.05), and an independent odds ratio of 4.9 (95% confidence interval, 1.05 to 22.65; P < 0.05). In conclusion, the D442G mutation is an independent risk factor for atherosclerotic complications in dialysis patients with HDL-C levels below 45 mg/dl.

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673